427 related articles for article (PubMed ID: 30742242)
21. An update on LAMA/LABA combinations for COPD.
Drug Ther Bull; 2017 Jan; 55(1):2-5. PubMed ID: 28057707
[TBL] [Abstract][Full Text] [Related]
22. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
Palli SR; Xie B; Chastek B; Elliott CA; Bengtson LGS
J Manag Care Spec Pharm; 2021 Jul; 27(7):810-824. PubMed ID: 33764161
[No Abstract] [Full Text] [Related]
23. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis.
Rogliani P; Matera MG; Ora J; Cazzola M; Calzetta L
Int J Chron Obstruct Pulmon Dis; 2017; 12():3469-3485. PubMed ID: 29255354
[TBL] [Abstract][Full Text] [Related]
24. Budesonide/Glycopyrronium/Formoterol: A Review in COPD.
Heo YA
Drugs; 2021 Aug; 81(12):1411-1422. PubMed ID: 34342835
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
Dahl R; Jadayel D; Alagappan VK; Chen H; Banerji D
Int J Chron Obstruct Pulmon Dis; 2013; 8():501-8. PubMed ID: 24159259
[TBL] [Abstract][Full Text] [Related]
27. Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β
Siddiqui MK; Shukla P; Jenkins M; Ouwens M; Guranlioglu D; Darken P; Biswas M
Ther Adv Respir Dis; 2019; 13():1753466619894502. PubMed ID: 31868101
[TBL] [Abstract][Full Text] [Related]
28. Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterol.
Malerba M; Morjaria JB; Radaeli A
Int J Chron Obstruct Pulmon Dis; 2014; 9():687-95. PubMed ID: 25061288
[TBL] [Abstract][Full Text] [Related]
29. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD.
Albertson TE; Bowman WS; Harper RW; Godbout RM; Murin S
Int J Chron Obstruct Pulmon Dis; 2019; 14():1251-1265. PubMed ID: 31239659
[TBL] [Abstract][Full Text] [Related]
30. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
Bourdin A; Molinari N; Ferguson GT; Singh B; Siddiqui MK; Holmgren U; Ouwens M; Jenkins M; De Nigris E
Adv Ther; 2021 Jun; 38(6):3089-3112. PubMed ID: 33929661
[TBL] [Abstract][Full Text] [Related]
32. Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.
Calzetta L; Di Marco F; Blasi F; Cazzola M; Centanni S; Micheletto C; Rossi A; Rogliani P
Pulm Pharmacol Ther; 2019 Dec; 59():101855. PubMed ID: 31639476
[TBL] [Abstract][Full Text] [Related]
33. [LAMA/LABA fixed dose combination for treatment of COPD].
Kuwahira I
Nihon Rinsho; 2016 May; 74(5):820-6. PubMed ID: 27254953
[TBL] [Abstract][Full Text] [Related]
34. Aclidinium bromide and formoterol fumarate for the maintenance treatment of chronic obstructive pulmonary disease.
Haley R; Gupta N; Sethi S
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):103-113. PubMed ID: 31951778
[No Abstract] [Full Text] [Related]
35. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
Ficker JH; Rabe KF; Welte T
Pulm Pharmacol Ther; 2017 Aug; 45():19-33. PubMed ID: 28389258
[TBL] [Abstract][Full Text] [Related]
36. Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update.
Matera MG; Rogliani P; Calzetta L; Cazzola M
Drug Saf; 2016 Jun; 39(6):501-8. PubMed ID: 26924197
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
Bateman ED; Mahler DA; Vogelmeier CF; Wedzicha JA; Patalano F; Banerji D
Expert Rev Respir Med; 2014 Jun; 8(3):357-79. PubMed ID: 24802656
[TBL] [Abstract][Full Text] [Related]
38. Dual bronchodilation in COPD: lung function and patient-reported outcomes - a review.
Price D; Østrem A; Thomas M; Welte T
Int J Chron Obstruct Pulmon Dis; 2017; 12():141-168. PubMed ID: 28115839
[TBL] [Abstract][Full Text] [Related]
39. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends.
Montuschi P; Ciabattoni G
J Med Chem; 2015 May; 58(10):4131-64. PubMed ID: 25587755
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review.
Ritondo BL; Puxeddu E; Calzetta L; Cazzola M; Rogliani P
Expert Opin Pharmacother; 2021 Apr; 22(5):611-620. PubMed ID: 33131340
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
